OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®, now commercially available in the U.S.
OMLYCLO ® (omalizumab-igec) is the first and only FDA-approved omalizumab biosimilar approved for all four indications of XOLAIR ® (omalizumab) and designated as interchangeable with XOLAIR; OMLYCLO ® will be available in 75 mg/0.5 mL, 150 mg/mL and...